Related references
Note: Only part of the references are listed.Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment
Sidney M. Gospe et al.
EYE (2021)
Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study
Jeremias Motte et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience
A. Segarra et al.
LUPUS (2020)
A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
Laura S. van Dam et al.
RHEUMATOLOGY (2020)
Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
Devis Benfaremo et al.
CELLS (2020)
Bortezomib improved the joint manifestations of rheumatoid arthritis in three patients
Slim Lassoued et al.
JOINT BONE SPINE (2019)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial
Siegfried Kohler et al.
BMJ OPEN (2019)
A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease
Qingdong Guan
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors
Tobias Alexander et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Regulatory T cells in autoimmune disease
Margarita Dominguez-Villar et al.
NATURE IMMUNOLOGY (2018)
Common ground: shared risk factors for type 1 diabetes and celiac disease
Elena F. Verdu et al.
NATURE IMMUNOLOGY (2018)
Approaches and advances in the genetic causes of autoimmune disease and their implications
Jamie R. J. Inshaw et al.
NATURE IMMUNOLOGY (2018)
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Multiple sclerosis
Massimo Filippi et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Severe refractory CIDP: a case series of 10 patients treated with bortezomib
Kalliopi Pitarokoili et al.
JOURNAL OF NEUROLOGY (2017)
Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder
Chao Zhang et al.
JAMA NEUROLOGY (2017)
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
Christiane Schneider-Gold et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes
Giada Mondanelli et al.
FRONTIERS IN IMMUNOLOGY (2017)
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Philipp M. Cromm et al.
ACS CENTRAL SCIENCE (2017)
Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjogren's syndrome
Fan Xiao et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura
Christopher J. Patriquin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Myasthenia gravis: subgroup classifications
Siegfried Kohler et al.
LANCET NEUROLOGY (2016)
Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis A case report and review of the literature
Junru Liu et al.
MEDICINE (2016)
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases
Sumita Ratnasingam et al.
BLOOD ADVANCES (2016)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow
Henrik E. Mei et al.
BLOOD (2015)
Human autoimmune diseases: a comprehensive update
Lifeng Wang et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Proteasome inhibitors as experimental therapeutics of autoimmune diseases
Sue Ellen Verbrugge et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Th17 cells play a critical role in the development of experimental Sjogren's syndrome
Xiang Lin et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice
Laleh Khodadadi et al.
PLOS ONE (2015)
Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient
Yu Wang et al.
RHEUMATOLOGY (2015)
Bortezomib for Refractory Autoimmunity in Pediatrics
Pooja Khandelwal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
Marshall A. Mazepa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib
Tessa van Balen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis Patients
Alejandro M. Gomez et al.
JOURNAL OF IMMUNOLOGY (2014)
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report
Sean Yates et al.
TRANSFUSION (2014)
Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity
Sladjana Andrejevic et al.
CLINICAL RHEUMATOLOGY (2013)
Autoimmune Rheumatic Diseases 3 Immunopathogenic mechanisms of systemic autoimmune disease
Marie Wahren-Herlenius et al.
LANCET (2013)
ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura
Jake Shortt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Alejandro M. Gomez et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS I (2012)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Proteasome Inhibitors: A New Perspective for Treating Autoimmune Diseases
Alessandra Fierabracci
CURRENT DRUG TARGETS (2012)
Mice completely lacking immunoproteasomes show major changes in antigen presentation
Eleanor Z. Kincaid et al.
NATURE IMMUNOLOGY (2012)
The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture
Nadine Hainz et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2012)
Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
Koichi Yanaba et al.
PLOS ONE (2012)
Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience
Eva Moran et al.
SEMINARS IN HEMATOLOGY (2012)
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
Karen Froehlich et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Proteasome Inhibition Aggravates Tumor Necrosis Factor-Mediated Bone Resorption in a Mouse Model of Inflammatory Arthritis
Karin Polzer et al.
ARTHRITIS AND RHEUMATISM (2011)
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
Makiko Hirai et al.
BLOOD (2011)
Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis
Alejandro M. Gomez et al.
JOURNAL OF IMMUNOLOGY (2011)
Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models
Asaf A. Qureshi et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares
A. Matrat et al.
LUPUS (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Falk Hiepe et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Proteasome Inhibitor Bortezomib Drastically Affects Inflammation and Bone Disease in Adjuvant-Induced Arthritis in Rats
Evangelia Yannaki et al.
ARTHRITIS AND RHEUMATISM (2010)
The auto-antigen repertoire in myasthenia gravis
Kathleen Vrolix et al.
AUTOIMMUNITY (2010)
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
Ulrike Seifert et al.
CELL (2010)
Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
Nicole Schmidt et al.
GUT (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Organization of immunological memory by bone marrow stroma
Koji Tokoyoda et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Bortezomib attenuates murine collagen-induced arthritis
S-W Lee et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo
Elisabeth Zinser et al.
IMMUNOBIOLOGY (2009)
UCH-L1 expression of podocytes in diseased glomeruli and in vitro
Yuan Liu et al.
JOURNAL OF PATHOLOGY (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Proteasome Inhibition Reduces Donor-Specific Antibody Levels
M. J. Everly et al.
TRANSPLANTATION PROCEEDINGS (2009)
Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches
Subhankar Paul
BIOESSAYS (2008)
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation
Nicolas Fissolo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
The myasthenia gravis thymus: A rare source of human autoantibody-secreting plasma cells for testing potential therapeutics
Marguerite E. Hill et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
Comparison of treatment strategies in early rheumatoid arthritis - A randomized trial
Yvonne P. M. Goekoop-Ruiterman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
A. L. Goldberg
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study
Yk Onno Teng et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Drug discovery in the ubiquitin-proteasome system
Grzegorz Nalepa et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells
A Nencioni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Medical progress:: Chronic inflammatory demyelinating polyneuropathy
H Köller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII
PM Kloetzel
NATURE IMMUNOLOGY (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes
M Belghith et al.
NATURE MEDICINE (2003)
Proteasome inhibition: a new anti-inflammatory strategy
PJ Elliott et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2003)
Proteasome inhibitors as new anticancer drugs
J Adams
CURRENT OPINION IN ONCOLOGY (2002)
Advances in immunology - Autoimmune diseases
A Davidson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A proteasome inhibitor effectively prevents mouse heart allograft rejection
HY Luo et al.
TRANSPLANTATION (2001)
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519
CL Vanderlugt et al.
JOURNAL OF AUTOIMMUNITY (2000)
Share Paper
